Skip to main content

Synergus

  • Home
  • About
    • Our Publications
    • Employment Opportunities
    • Intern/Thesis Opportunities
    • Find Us
    • Privacy Policy
    • Contact Us
    • IGES group
  • RWE impact
    • Data that makes the difference
    • Real World Data / Statistical analysis
    • Evidence For Decisions
  • Market Access
    • Countries
    • Diagnostics
    • Digital Health
    • Medical Device
      • Market access strategy
      • Hands-on market access support
      • Reimbursement dossier / HTA dossier
      • Reimbursement/DRG analysis
    • Pharma
  • HEOR
    • Health Economics
      • Cost Effectiveness and Budget Impact Modelling
      • Economic Outcomes in Clinical Studies
    • Value Demonstration
  • Events/Webinars
  • News
  • Blog

You are here

Home ยป Blog
  • Home
  • About
    • Our Publications
    • Employment Opportunities
    • Intern/Thesis Opportunities
    • Find Us
    • Privacy Policy
    • Contact Us
  • RWE impact
    • Data that makes the difference
    • Real World Data / Statistical analysis
    • Evidence For Decisions
  • Market Access
    • Countries
    • Diagnostics
    • Digital Health
    • Medical Device
      • Market access strategy
      • Reimbursement/DRG analysis
      • Reimbursement dossier / HTA dossier
      • Hands-on market access support
    • Pharma
  • HEOR
    • Health Economics
      • Cost Effectiveness and Budget Impact Modelling
      • Economic Outcomes in Clinical Studies
    • Value Demonstration
  • Events/Webinars
  • News
  • Blog
Use of generic quality of life measures in reports from NICE
11 Apr 2016

We are evolving the insight in the data we have in our HTA update search platform. In this analysis we looked at the occurrence of the two major quality of life measures, EQ-5D and SF-36, in reports from NICE in the United Kingdom. Learn more about our service here:

  • HTA Update Search
  • Patient reported outcomes

 

Tags: 

  • Quality of Life
  • United Kingdom
  • SF-36
  • EQ-5D
  • HTA
  • LinkedIn
  • Twitter

Contact us

Tags

Breast cancer
Corona virus
DHS France
EMA
EQ-5D
EU HTAR
EU HTAR IVD
EU HTAR Medtech
Germany
HQ_RWD
Imaging
Myeloma
Obesity
Patient Registries
Pharma
RWD Scientific Impact
RWD_DK
Transferability of Outcomes
Coverage with Evidence Development
DHS Germany
Italy
Melanoma
Multiple Sclerosis
Quality of Life
R-RCT
Registries
SF-36
DHS Belgium
Funding
HQRWE_Fracture
Netherlands
Rheumatoid Arthritis
Throat Cancer
Co-payment
Empowered Patients
Lung Cancer
Norway
Stroke
Digital Heath Strategies
France
Innovation Funding
Mental Health
Data Science in Oncology
Finland
Heart Failure
Out-patient procedures
Artificial Intelligence
Denmark
Diabetes
Dementia
Sweden
Alzheimer
The Netherlands
Oncology
United Kingdom
Country specific
China
COVID-19
Value Based Healthcare
HTA
RefugeeMD
Medical Device
Disease Specific
Health Economics
Legislation
Market Access
IVD
Digital Health
Real World Data
Real World Evidence
  • Home
  • About
  • RWE impact
  • Market Access
  • HEOR
  • Events/Webinars
  • News
  • Blog